Zacks Research Has Bullish Forecast for BMRN Q3 Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) - Zacks Research upped their Q3 2026 EPS estimates for shares of BioMarin Pharmaceutical in a research note issued to investors on Wednesday, July 16th. Zacks Research analyst S. Ganoria now expects that the biotechnology company will post earnings per share of $1.08 for the quarter, up from their previous estimate of $1.07. The consensus estimate for BioMarin Pharmaceutical's current full-year earnings is $3.15 per share. Zacks Research also issued estimates for BioMarin Pharmaceutical's FY2026 earnings at $4.26 EPS and Q2 2027 earnings at $1.20 EPS.

A number of other equities research analysts also recently weighed in on BMRN. Citigroup reduced their price target on shares of BioMarin Pharmaceutical from $82.00 to $78.00 and set a "neutral" rating on the stock in a research note on Friday, May 2nd. JPMorgan Chase & Co. increased their price objective on shares of BioMarin Pharmaceutical from $108.00 to $113.00 and gave the company an "overweight" rating in a research note on Monday, July 14th. The Goldman Sachs Group decreased their target price on shares of BioMarin Pharmaceutical from $124.00 to $104.00 and set a "buy" rating on the stock in a research note on Monday, May 5th. Morgan Stanley assumed coverage on shares of BioMarin Pharmaceutical in a report on Thursday, July 3rd. They set an "overweight" rating and a $97.00 price target for the company. Finally, Wall Street Zen cut BioMarin Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Friday. Six equities research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $93.78.

BioMarin Pharmaceutical Stock Performance

BioMarin Pharmaceutical stock opened at $57.29 on Monday. The company has a quick ratio of 3.49, a current ratio of 5.52 and a debt-to-equity ratio of 0.10. The stock has a market cap of $10.99 billion, a PE ratio of 21.30, a P/E/G ratio of 0.79 and a beta of 0.17. BioMarin Pharmaceutical has a 12-month low of $52.93 and a 12-month high of $94.85. The business's 50-day moving average price is $57.21 and its two-hundred day moving average price is $62.32.

Insider Activity

In other news, CAO Erin Burkhart sold 1,786 shares of the stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $59.31, for a total transaction of $105,927.66. Following the completion of the sale, the chief accounting officer directly owned 14,173 shares in the company, valued at $840,600.63. This represents a 11.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 0.85% of the company's stock.

Institutional Trading of BioMarin Pharmaceutical

A number of institutional investors have recently bought and sold shares of the company. Rise Advisors LLC acquired a new position in shares of BioMarin Pharmaceutical in the 1st quarter valued at about $30,000. Farther Finance Advisors LLC increased its holdings in BioMarin Pharmaceutical by 95.9% in the first quarter. Farther Finance Advisors LLC now owns 431 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 211 shares in the last quarter. V Square Quantitative Management LLC acquired a new position in BioMarin Pharmaceutical in the second quarter valued at approximately $25,000. LRI Investments LLC boosted its holdings in shares of BioMarin Pharmaceutical by 856.9% during the 4th quarter. LRI Investments LLC now owns 488 shares of the biotechnology company's stock worth $32,000 after buying an additional 437 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB boosted its holdings in shares of BioMarin Pharmaceutical by 71.2% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 524 shares of the biotechnology company's stock worth $37,000 after buying an additional 218 shares in the last quarter. Institutional investors own 98.71% of the company's stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.